Ipsen continues its long-standing commitment to a multi-modal approach to treating mobility impairment in adult and pediatric patients and improving their quality of life.
Long-term commitment, high ambitions
Since 1990, Ipsen has focused on pioneering research in neurotoxins and more recently on recombinant neurotoxin engineering. Our drug treatment Dysport® is based on the type-A botulinum toxin, which inhibits the transmission of nerve impulses to the muscle. Botulinum toxin injections cause contracted muscles to relax, relieving
patients’ symptoms and helping to improve the quality of their daily lives.
The recent approval in the United States of Dysport® for the treatment of upper limb spasticity in adults and lower limb spasticity in children aged 2 and older was a strong endorsement of our clinical trials.
Clinical trials are underway to generate additional data in support of therapeutic uses of Dysport®. In areas where national labels are currently in place, the Group will submit evidence in support of improved Dysport® labeling for adult and pediatric spasticity.
Ipsen aims to explore and develop additional Dysport® indications in neurology and urology (as with neurogenic detrusor overactivity, a condition often associated in patients with multiple sclerosis, or spinal cord injuries).
Research is underway on the development of a liquid formulation for both Aesthetics and Therapeutic uses.
We are dedicated on our ambition to lead and shape the future of neurotoxins. Ongoing eff orts to advance our innovative recombinant toxin platform drives each Ipsen associate to exceed today’s standards and provide better therapies to the patients we serve.
Engagements for patient care
Ipsen has built a strong, long-term partnership with Dystonia Europe, an organization representing dystonia patients
across the continent, and with the American Dystonia Society. We also continue to support initiatives for physicians who seek further research in cervical dystonia, disease awareness campaigns for patients and the creation of patient networks in Europe.
Ipsen’s I-CAN program is an innovative spasticity management program that engages patients in their own treatment.
Commitments to healthcare professionals
Ipsen provides ongoing local and regional training for physicians who want to improve results using Dysport®. Ipsen’s long-running “Ixcellence Network” trains physicians in more than 20 countries and helps them set goals for self-guided rehabilitation. For aesthetics practitioners, our educational master classes increase clinical and practical expertise for better outcomes.
Partnership with Galderma
In aesthetic medicine Ipsen has granted the right to distribute Dysport® in aesthetic medicine to Galderma, a pharmaceutical company specializing in the research, development and marketing of dermatological treatments. As a function of the partnership Ipsen predominantly promotes therapeutic indications for Dysport®, while Galderma distributes aesthetic treatment under the brand names of Dysport® and Azzalure®. Under the terms of the partnership, Ipsen and Galderma also collaborate on the future development and commercialization of new neurotoxin therapies.
The partnership with Galderma now includes the United States, Canada, Europe, Brazil, Australia and some Asia-Pacific countries.
Dysport®, one product for a range of indications
Dysport® was first registered for the treatment of blepharospasm in the United Kingdom in 1990 and has been marketed since 1991. Today, Dysport® is used primarily for patients with spasticity, cervical dystonia, hemifacial spasm, blepharospasm, and hyperhidrosis. In aesthetic medicine, Dysport® is indicated for the reduction of glabellar lines (frown lines). Dysport® is authorized in more than 80 countries for 7 therapeutic and aesthetic indications.
Ipsen is committed to continuing a tradition of delivering high-level scientific evidence with current post-marketing studies such as: the On-Time pilot study, focused on early treatment with Dysport® in stroke patients, and the Upper Limb International Spasticity (ULIS) study, involving 1,000 people in 14 countries. A newly launched ENGAGE study was launched in 2016 to assess the effect of abobotulinumtoxinA administered simultaneously in upper and lower limbs in conjunction with a guided selfrehabilitation contract in adult patients with spastic hemiparesis.
Botulinum toxins have the potential for broad applications across multiple therapeutic areas, including urology, neurology, oncology, endocrinology and regenerative medicine.
Ipsen is planning for the future with research on new recombinant botulinum toxins and on the promising area of targeted secretion inhibition.
Collaborative partnerships with renowned university research centers are ongoing and at the center of finding new ways to use our neurotoxin pipeline to combat debilitating conditions that burden the lives of patients.
Research partnerships continue with Harvard University, while a new research partnership with the IMCB in Singapore, under the aegis of the Agency for Science, Technology and Research (A*STAR) , aim to advance understanding of botulinum neurotoxin biology.
Commitment to spasticity in multiple sclerosis
Ipsen and GW Pharmaceuticals have an agreement giving Ipsen promotion and distribution rights in Latin America for Mevatyl®, an oromucosal spray indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis. GW Pharmaceuticals and Ipsen are conducting regulatory filings in selected countries in Latin America for this indication and have won approval for it in Brazil.
Sales in neurosciences in 2016
(18.1% of sales in 2016)
Expertise in neurotoxins
Patents in neurology